Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web address) of an individual response, simply click on the response headline and copy the URL from the browser window. A proportion of responses will, after editing, be published online and in the print journal as letters, which are indexed in PubMed. Rapid responses are not indexed in PubMed and they are not journal articles. The BMJ reserves the right to remove responses which are being wilfully misrepresented as published articles.
The price of monoclonal antibodies bears little relationship to the development and production costs.(1). Denosumab, a highly specific monoclonal antibody, which incidentally is advertised on the back cover of this issue of BMJ, costs the NHS only £310 pounds per dose.
The pricing of a near monopoly product is always related to 'how much the market can bear'. Markets tend be ‘inefficient’ with monopoly products and suppliers.
In 1914, faced with rising drug prices, the BMA Pharmaceutical Committee, recommended that ‘Government should exercise its powers’ to control price inflation. Perhaps that advice still remains relevant today.(2)
1. Shaughnessy AF. Monoclonal antibodies: magic bullets with a hefty price tag. BMJ. 2012 Dec 12;345(dec12 1):e8346–e8346.
2. Price of Drugs. Supplement 542. BMJ. 1914 Sep 12;2(2802):S169–S172.
Honararia from various pharmaceutical companies including Amgen, Sanofi and Roche.